Imperial College London

ProfessorAnneBowcock

Faculty of MedicineNational Heart & Lung Institute

Visiting Professor
 
 
 
//

Contact

 

+44 (0)20 7594 1511a.bowcock

 
 
//

Location

 

Guy Scadding BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Luke:2014:10.1111/pcmr.12304,
author = {Luke, JJ and Triozzi, PL and McKenna, KC and Van, Meir EG and Gershenwald, JE and Bastian, BC and Gutkind, JS and Bowcock, AM and Streicher, HZ and Patel, PM and Sato, T and Sossman, JA and Sznol, M and Welch, J and Thurin, M and Selig, S and Flaherty, KT and Carvajal, RD},
doi = {10.1111/pcmr.12304},
journal = {Pigment Cell & Melanoma Research},
pages = {135--147},
title = {Biology of advanced uveal melanoma and next steps for clinical therapeutics},
url = {http://dx.doi.org/10.1111/pcmr.12304},
volume = {28},
year = {2014}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Uveal melanoma is the most common intraocular malignancy although it is a rare subset of all melanomas. Uveal melanoma has distinct biology relative to cutaneous melanoma, with widely divergent patient outcomes. Patients diagnosed with a primary uveal melanoma can be stratified for risk of metastasis by cytogenetics or gene expression profiling, with approximately half of patients developing metastatic disease, predominately hepatic in location, over a 15-yr period. Historically, no systemic therapy has been associated with a clear clinical benefit for patients with advanced disease, and median survival remains poor. Here, as a joint effort between the Melanoma Research Foundation's ocular melanoma initiative, CURE OM and the National Cancer Institute, the current understanding of the molecular and immunobiology of uveal melanoma is reviewed, and on-going laboratory research into the disease is highlighted. Finally, recent investigations relevant to clinical management via targeted and immunotherpies are reviewed, and next steps in the development of clinical therapeutics are discussed.
AU - Luke,JJ
AU - Triozzi,PL
AU - McKenna,KC
AU - Van,Meir EG
AU - Gershenwald,JE
AU - Bastian,BC
AU - Gutkind,JS
AU - Bowcock,AM
AU - Streicher,HZ
AU - Patel,PM
AU - Sato,T
AU - Sossman,JA
AU - Sznol,M
AU - Welch,J
AU - Thurin,M
AU - Selig,S
AU - Flaherty,KT
AU - Carvajal,RD
DO - 10.1111/pcmr.12304
EP - 147
PY - 2014///
SN - 1755-148X
SP - 135
TI - Biology of advanced uveal melanoma and next steps for clinical therapeutics
T2 - Pigment Cell & Melanoma Research
UR - http://dx.doi.org/10.1111/pcmr.12304
UR - http://hdl.handle.net/10044/1/40223
VL - 28
ER -